"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • For Professionals
  • FDA Approvals
  • FDA Approves olaparib (Lynparza) for adult patients with deleterious or suspected deleterious (gBRCAm or sbrcam) advanced epithelial ovarian cancer

FDA Approves olaparib (Lynparza) for adult patients with deleterious or suspected deleterious (gBRCAm or sbrcam) advanced epithelial ovarian cancer

14 Jan 2019 2:26 PM | Anonymous

The U.S. Food and Drug Administration approved olaparib (Lynparza; AstraZeneca Pharmaceuticals) for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Read full press release.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software